Baicalin administration attenuates hyperglycemia-induced malformation of cardiovascular system

Guang Wang, Jianxin Liang, Lin-Rui Gao, Zhen-Peng Si, Xiao-Tan Zhang, Guo Liang, Yu Yan, Ke Li, Xin Cheng, Yongping Bao, Manli Chuai, Li-Guo Chen, Da-Xiang Lu, Xuesong Yang (Lead / Corresponding author)

Research output: Contribution to journalArticle

12 Citations (Scopus)
153 Downloads (Pure)

Abstract

In this study, the effects of Baicalin on the hyperglycemia-induced cardiovascular malformation during embryo development were investigated. Using early chick embryos, an optimal concentration of Baicalin (6 μM) was identified which could prevent hyperglycemia-induced cardiovascular malformation of embryos. Hyperglycemia-enhanced cell apoptosis was reduced in embryos and HUVECs in the presence of Baicalin. Hyperglycemia-induced excessive ROS production was inhibited when Baicalin was administered. Analyses of SOD, GSH-Px, MQAE and GABAA suggested Baicalin plays an antioxidant role in chick embryos possibly through suppression of outwardly rectifying Cl(-) in the high-glucose microenvironment. In addition, hyperglycemia-enhanced autophagy fell in the presence of Baicalin, through affecting the ubiquitin of p62 and accelerating autophagy flux. Both Baicalin and Vitamin C could decrease apoptosis, but CQ did not, suggesting autophagy to be a protective function on the cell survival. In mice, Baicalin reduced the elevated blood glucose level caused by streptozotocin (STZ). Taken together, these data suggest that hyperglycemia-induced embryonic cardiovascular malformation can be attenuated by Baicalin administration through suppressing the excessive production of ROS and autophagy. Baicalin could be a potential candidate drug for women suffering from gestational diabetes mellitus.

Original languageEnglish
Article number234
Pages (from-to)1-17
Number of pages17
JournalCell Death and Disease
Volume9
Issue number2
DOIs
Publication statusPublished - 14 Feb 2018

Fingerprint Dive into the research topics of 'Baicalin administration attenuates hyperglycemia-induced malformation of cardiovascular system'. Together they form a unique fingerprint.

  • Cite this

    Wang, G., Liang, J., Gao, L-R., Si, Z-P., Zhang, X-T., Liang, G., Yan, Y., Li, K., Cheng, X., Bao, Y., Chuai, M., Chen, L-G., Lu, D-X., & Yang, X. (2018). Baicalin administration attenuates hyperglycemia-induced malformation of cardiovascular system. Cell Death and Disease, 9(2), 1-17. [234]. https://doi.org/10.1038/s41419-018-0318-2